Literature DB >> 24005232

Absence of FLICE-inhibitory protein is a novel independent prognostic marker for very short survival in pancreatic ductal adenocarcinoma.

Sandra J Schmid1, Marie-Charlotte Glatzel, Claudia Welke, Marko Kornmann, Alexander Kleger, Thomas F E Barth, Simone Fulda, Jochen K Lennerz, Peter Möller.   

Abstract

OBJECTIVES: Evading apoptosis is a hallmark of pancreatic cancer. In pancreatic cancer models, chemotherapy down-regulates the antiapoptotic protein cellular FLICE inhibitory protein (c-FLIP), which renders cells sensitive to apoptosis. Currently, the relevance of c-FLIP expression as a biomarker in pancreatic cancer is unknown, and here we assessed the prognostic significance of the c-FLIP expression status in a large cohort of pancreatic cancer patients with clinical follow-up.
METHODS: Cellular FLICE inhibitory protein expression levels were determined by immunohistochemistry in 120 surgically resected ductal pancreatic adenocarcinomas. Survival analysis by c-FLIP status was compared with established clinicopathologic biomarkers as well as Ki-67 and cyclooxygenase 2 expression levels as 2 other established independent prognostic biomarkers in pancreatic cancer.
RESULTS: Of 120 tumors, 111 (91%) were c-FLIP positive, whereas 9 (9%) were completely c-FLIP negative. Cyclooxygenase 2 was positive in 59 cases (52%), and Ki-67 was positive in more than 10% of tumor cells in 51 cases (44%). Univariate and multivariate survival analysis (correcting for stage, grade, and proliferation index) showed that c-FLIP is an independent prognostic factor. Specifically, c-FLIP negativity identifies 9% of patients with a highly aggressive disease course (P = 0.0001).
CONCLUSIONS: Cellular FLICE inhibitory protein expression status is a valuable prognostic biomarker in pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24005232     DOI: 10.1097/MPA.0b013e31829655ed

Source DB:  PubMed          Journal:  Pancreas        ISSN: 0885-3177            Impact factor:   3.327


  6 in total

1.  Jaundice in resected pancreatic cancer patients.

Authors:  Fenja M Feld; Jochen K Lennerz
Journal:  HPB (Oxford)       Date:  2014-02       Impact factor: 3.647

Review 2.  Systematic review of peri-operative prognostic biomarkers in pancreatic ductal adenocarcinoma.

Authors:  Wilson Petrushnko; Justin S Gundara; Philip R De Reuver; Greg O'Grady; Jaswinder S Samra; Anubhav Mittal
Journal:  HPB (Oxford)       Date:  2016-07-14       Impact factor: 3.647

3.  Prognostic significance of cyclooxygenase-2 protein in pancreatic cancer: a meta-analysis.

Authors:  Di Wang; Xiao-Zhong Guo; Hong-Yu Li; Jia-Jun Zhao; Xiao-Dong Shao; Chun-Yan Wu
Journal:  Tumour Biol       Date:  2014-07-18

4.  Prognostic Value of COX-2, NF-κB, and Sp1 Tissue Expressions in Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-analysis.

Authors:  Kaka Renaldi; Marcellus Simadibrata; Nur Rahadiani; Diah Rini Handjari; Andy William; Fira Sinuraya; Dadang Makmun
Journal:  Turk J Gastroenterol       Date:  2021-11       Impact factor: 1.852

5.  GOT1/AST1 expression status as a prognostic biomarker in pancreatic ductal adenocarcinoma.

Authors:  Fenja M Feld; Philipp D Nagel; Stephanie E Weissinger; Claudia Welke; Albrecht Stenzinger; Peter Möller; Jochen K Lennerz
Journal:  Oncotarget       Date:  2015-02-28

6.  Single-cell-resolved differentiation of human induced pluripotent stem cells into pancreatic duct-like organoids on a microwell chip.

Authors:  Sandra Wiedenmann; Markus Breunig; Jessica Merkle; Christine von Toerne; Tihomir Georgiev; Michel Moussus; Lucas Schulte; Thomas Seufferlein; Michael Sterr; Heiko Lickert; Stephanie Ellen Weissinger; Peter Möller; Stefanie M Hauck; Meike Hohwieler; Alexander Kleger; Matthias Meier
Journal:  Nat Biomed Eng       Date:  2021-07-08       Impact factor: 25.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.